# Affymax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/affymax

- Industry: Pharmaceuticals
- Headquarters: Palo Alto, US
- Website: www.affymax.com
- Total disclosed funding: $70M
- Latest round: Series E (Apr 11, 2006)
- Investors on record: 9

## About

Affymax Inc. is a biopharmaceutical company specializing in the development of novel therapies for anemia related to chronic kidney disease, providing innovative solutions to improve patient care.Founded in 2001 in Palo Alto, US, Affymax Inc. focuses on creating groundbreaking treatments for anemia and has undergone significant development since its inception. The company successfully completed an IPO in December 2006, valued at USD 92.50 mn, with 3.7 million shares offered at an exit price of USD 25 on the NASDAQ. The latest investment round, PIPE, raised USD 42.00 mn, led by ProQuest Investments, with participation from BVF Partners, Bessemer Venture Partners, and Sprout Group. Affymax has completed a total of 6 deals as of December 2006, the date of its latest transaction.Affymax Inc. offers innovative biopharmaceutical products aimed primarily at addressing anemia associated with chronic kidney disease. Their lead product is designed to stimulate erythropoiesis, improving hemoglobin levels in patients. The company focuses on developing therapies that meet the unmet medical needs in this critical area, leveraging advanced research to enhance health outcomes for patients.In the most recent year, 2013, Affymax reported revenues of USD 1,369,000 with an EBITDA of USD -14,323,000, reflecting the challenges faced during its operational period.Affymax plans to utilize the recent funding to further its research and development efforts, focusing on launching new therapeutics aimed at treating anemia by the end of 2007. The company aims to expand its market presence, particularly in North America and Europe, by enhancing its sales and marketing capabilities. The strategic allocation of funds will support the development of additional products and facilitate entry into new geographical regions, enhancing the overall portfolio of solutions offered to healthcare providers.

## Funding rounds

- Series E, Apr 11, 2006, $10M — Apax Partners, Sprout Group, JAFCO Group, MPM BioImpact, Bear Stearns Health Innoventures
- Series D, Jul 18, 2005, $60M — Apax Partners, Sprout Group, Merlin Partners, Bessemer Venture Partners, Icon Ventures, MPM BioImpact, Diamond Equity Partners, Bear Stearns Health Innoventures

## Investors

- Apax Partners (https://capitalatlas.ai/funds/apax-partners) — Series D, Series E
- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series D, Series E
- Merlin Partners (https://capitalatlas.ai/funds/merlin-partners) — Series D
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series D
- Icon Ventures (https://capitalatlas.ai/funds/icon-ventures) — Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series D, Series E
- Diamond Equity Partners (https://capitalatlas.ai/funds/diamond-equity-partners) — Series D
- Bear Stearns Health Innoventures (https://capitalatlas.ai/funds/bear-stearns-health-innoventures) — Series D, Series E
- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series E